Clinical Trials
27 trialsReduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
ABCD-NK
Washington University School of Medicine
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Washington University School of Medicine
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Case Comprehensive Cancer Center
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Weill Medical College of Cornell University
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Duke University
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Tufts Medical Center
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
PETHEMA Foundation
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Washington University School of Medicine
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
AMD3100+MEC
Washington University School of Medicine
AML
Washington University School of Medicine
Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection
University Health Network, Toronto
AML18 Pilot
Cardiff University
BMTAMD3100
Emory University
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital